Stroke is the leading cause of disability and thesecond leading cause of death worldwide.
With the global population aged 65 and over growing faster than all other age groups, the …

Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …

Previous genome-wide association studies (GWASs) of stroke—the second leading cause of
death worldwide—were conducted predominantly in populations of European ancestry …

Hemorrhagic transformation (HT) is a common complication in patients with acute ischemic
stroke. It occurs when peripheral blood extravasates across a disrupted blood brain barrier …

Ischemic stroke is the main cause of death and the most common cause of acquired physical
disability worldwide. Recent demographic changes increase the relevance of stroke and its …

Proteases are signaling molecules that specifically control cellular functions by cleaving
protease-activated receptors (PARs). The four known PARs are members of the large family …

Ischaemic stroke is a leading cause of disability and death for which no acute treatments
exist beyond recanalization. The development of novel therapies has been repeatedly …

Investigators acknowledge the limitations of rodent or non-human primate stroke models,
hundreds of putative neuroprotectants have been evaluated in preclinical models, but not …

We search for ischemic stroke treatment knowing we have failed—intensely and often—to
translate mechanistic knowledge into treatments that alleviate our patients' functional …

Traumatic brain injury (TBI) is one the most common human afflictions, contributing to long-
term disability in survivors. Emerging data indicate that functional improvement or …